|
NFX1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.8512973072643E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.65529964472E-10 |
| Normal-vs-Stage2 |
1.02459999995475E-06 |
| Normal-vs-Stage3 |
1.15079945572916E-10 |
| Normal-vs-Stage4 |
2.66800004311563E-09 |
| Stage1-vs-Stage2 |
4.594200E-01 |
| Stage1-vs-Stage3 |
1.127400E-01 |
| Stage1-vs-Stage4 |
2.119400E-01 |
| Stage2-vs-Stage3 |
7.213400E-01 |
| Stage2-vs-Stage4 |
7.383400E-01 |
| Stage3-vs-Stage4 |
9.852800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.37899691665666E-11 |
| Normal-vs-AfricanAmerican |
2.238700E-04 |
| Normal-vs-Asian |
1.89416999999414E-05 |
| Caucasian-vs-AfricanAmerican |
6.039400E-01 |
| Caucasian-vs-Asian |
3.051600E-01 |
| AfricanAmerican-vs-Asian |
8.229400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.38570282920614E-11 |
| Normal-vs-Female |
9.35089783382637E-11 |
| Male-vs-Female |
4.031600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.26229995742489E-09 |
| Normal-vs-Age(41-60Yrs) |
3.25410032253615E-10 |
| Normal-vs-Age(61-80Yrs) |
2.44849696073857E-11 |
| Normal-vs-Age(81-100Yrs) |
1.579190E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.402600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.946500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.734600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.357200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.231000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.902000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.678500E-02 |
| Classical-VS-Follicular |
5.368400E-02 |
| Classical-VS-Other |
3.612200E-01 |
| Classical-VS-Normal |
8.16720024943152E-10 |
| Tall-VS-Follicular |
8.671800E-01 |
| Tall-VS-Other |
9.703800E-01 |
| Tall-VS-Normal |
1.17729999971061E-07 |
| Follicular-VS-Other |
9.201000E-01 |
| Follicular-VS-Normal |
1.625199996802E-08 |
| Other-VS-Normal |
2.700100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.61319965666473E-10 |
| Normal-vs-N1 |
5.61649999841762E-08 |
| N0-vs-N1 |
7.118200E-01 |
|
|
